INSM vs. TEM: Insmed vs. Tempus AI Stock Comparison

Company Profile

Insmed (INSM) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INSM is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Insmed (INSM) carries decades of public-market history since June 1, 2000, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the INSM side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas Insmed (INSM) is closer to market-like at 0.80 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Insmed (INSM) at -72.45% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Both Insmed (INSM) at -39.85% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

Both Insmed (INSM) at -15.60% and Tempus AI (TEM) at -13.82% report negative operating margin values, usually indicating operating losses over the period.

Profitability Metrics

Growth

Both Insmed (INSM) at 66.73% and Tempus AI (TEM) at 83.41% sit in the top peer quartile for revenue growth, so each is growing its top line faster than typical industry peers.

Neither Insmed (INSM) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Insmed (INSM) at 2.86 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: Insmed (INSM) at 1.01 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither Insmed (INSM) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Insmed (INSM) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither Insmed (INSM) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

On P/S ratio, both Insmed (INSM) at 16.52 and Tempus AI (TEM) at 9.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Measured against book value, both Insmed (INSM) at 34.55 and Tempus AI (TEM) at 27.66 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics